Savant Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Savant Capital’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25,000	Closed	-$21K	–	424
2020 Q1	$21K	Hold	25,000	–	–	﹤0.01%	373
2019 Q4	$24K	Hold	25,000	–	–	﹤0.01%	349
2019 Q3	$26K	Hold	25,000	–	–	﹤0.01%	325
2019 Q2	$45K	Hold	25,000	–	–	0.01%	330
2019 Q1	$47K	Hold	25,000	–	–	0.01%	280
2018 Q4	$29K	Buy	25,000 +10,000	+67%	+$18K	0.01%	259
2018 Q3	$41K	Sell	15,000 -7,000	-32%	-$14.5K	0.01%	294
2018 Q2	$42K	Hold	22,000	–	–	0.01%	285
2018 Q1	$46K	Buy	22,000 +5,750	+35%	+$12.3K	0.01%	284
2017 Q4	$33K	Buy	+16,250	New	+$33.7K	0.01%	283

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Savant Capital's INFI Position: Q2 2020 in Review

Savant Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2020, closing a stake of 25,000 shares — an estimated $21K sold.

Savant Capital first reported a position in INFI in Q4 2017 and held it in 10 quarters. The position peaked at $47K in Q1 2019. 48 funds tracked by Wall St. Rank hold INFI as of Q2 2020.

Savant Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Savant Capital sold 25,000 Infinity Pharmaceuticals, Inc. shares in Q2 2020, an estimated $21K.
Savant Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2017 and held it in 10 quarters.
Savant Capital's Infinity Pharmaceuticals, Inc. position peaked at $47K in Q1 2019.
48 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2020.

Based on Savant Capital's 13F filing for Q2 2020, filed 11 Aug 2020.